By Ed Susman Special to DG News BERLIN, GERMANY —
September 5, 2002 —
High risk hypertensive patients — particularly those with diabetes — appear to do better on the investigative vasopeptidase inhibitor omapatrilat than on the angiotensin-converting enzyme inhibitor enalapril, researchers reported at the 24th annual congress of the European Society of Cardiology.
“Omapatrilat is consistently more efficacious than enalapril in reducing systolic blood pressure and achieving blood pressure control,” said Michael A. Weber, MD, associate dean and professor of medicine at the State University of New York Health Science Center at Brooklyn.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!